Follow Us On

Facebook  X  Linkedin  YouTube
 
 

ASIPP 2027–2028

Board Nominations Underway

Nomination Deadline: October 1, 2026


ASIPP is now accepting nominations for its 2027–2028 Board of Directors. Every two years, members elect officers and directors-at-large who will help guide the Society.


ASIPP members received an email this morning at 6:30 a.m. CT with a link to the nomination ballot. Nominations are due no later than October 1, 2026.


Serving on the ASIPP Board is an opportunity to help shape the future of interventional pain management and represent our membership. We encourage nominations from across ASIPP to ensure a strong and diverse group of leaders.


Check your inbox and submit your nominations today!


If you did not receive this e-mail, please notify Karen Avery at kavery@asipp.org.

 

The Department of Veterans Affairs (VA) has announced that precertification is no longer required for Community Care Network (CCN) providers before providing authorized care for Veterans.


The additional prior authorization/precertification requirement has been postponed, and the VA Precertification Portal (VAPP) is being taken offline.


Providers should continue delivering care in accordance with existing VA authorizations and Standard Episodes of Care (SEOCs).


Click here to read the full update from ASIPP.

ASIPP Submits Comment Letters to CMS on Key CY 2027 Medicare Policies


The American Society of Interventional Pain Physicians (ASIPP) submitted four comment letters to the Centers for Medicare & Medicaid Services (CMS) addressing important policy, payment, and coding issues affecting interventional pain physicians, independent practices, ambulatory surgery centers, and Medicare beneficiaries. The letters address the CY 2027 Physician Fee Schedule proposed rule, the Ambulatory Specialty Model (ASM), proposed changes to ambulatory surgical center payments and neuromodulation procedure reimbursement, and CMS’s Request for Information regarding the Current Procedural Terminology (CPT) coding and valuation process. Across these comments, ASIPP continues to advocate for appropriate reimbursement, preservation of independent practices, continued beneficiary access to non-opioid interventional pain care, and greater transparency and fairness in Medicare payment and coding policies.


Read the full comment letters:





Gabapentin Use Rose as Restrictions Fell, Study Shows

Descheduling gabapentin in Michigan was tied to an immediate increase in dispensing

 

Key Takeaways


• Gabapentin is one of the top prescribed medications in the U.S. and is often used off-label for chronic pain.


• In 2019, Michigan enacted legislation to schedule gabapentin as a controlled substance but rescinded its policy in 2024.


• After gabapentin was descheduled, dispensing immediately rose among Michigan Medicaid patients.

Gabapentin use jumped quickly in Michigan after the drug was removed from the state's controlled substance schedule in 2024, a cross-sectional study showed.


From 2023 through 2025, gabapentin dispensing in the Michigan Medicaid program ranged from 33 to 43 prescriptions per 1,000 enrollees, while pregabalin dispensing remained consistently lower, reported Juan Hincapie-Castillo, PharmD, MS, PhD, of the University of Pittsburgh, and co-authors.


Click here to read the full article.

 
 

The Comments Worked — Partly. What the Final Peripheral Nerve LCDs Give Back, and What They Still Take.


For ASIPP members.

Effective for services on or after October 25, 2026.

Eleven months ago, five Medicare Administrative Contractors proposed to end coverage for nearly every peripheral nerve intervention in chronic pain. Occipital. Stellate ganglion. Suprascapular. Genicular. Pudendal. Posterior tibial. Thoracic. Digital. Ulnar. Three procedures would have survived: radiofrequency neurolysis for trigeminal neuralgia, three lifetime corticosteroid injections for median neuropathy at the wrist, two lifetime injections for Morton’s neuroma. Complex regional pain syndrome was named as investigational.


The finals posted September 10, 2026. They are not what was proposed.


That difference did not happen on its own, and members should understand clearly what produced it. ASIPP filed. So did ASA, AAPM, ASRA, AANA, the Multisociety Pain Workgroup, state medical associations, and eventually the AMA House of Delegates, which adopted a resolution in November 2025 and followed with a formal letter to CMS in December. The contractors read the submissions. We know this because they tell us, section by section, exactly how many systematic reviews, randomized trials, observational studies, and guidelines arrived during the comment period and precisely what each body of evidence changed.


That is the most important thing in these documents, and it is not a coverage criterion. It is a demonstration that a well-evidenced comment campaign moves a multi-jurisdictional LCD.


First, understand what you are actually reading

There are five LCD numbers. There is one policy.

Remove the contractor table from the top of each document and the remaining text is identical — not comparable, identical. Same definitions, same twelve-item limitations list, same Kellgren-Lawrence thresholds, same bibliography numbering.


The operational consequence is that a reconsideration request filed with CGS does not move Palmetto, and a favorable ALJ decision in Ohio establishes nothing in Missouri. Future advocacy has to be filed five times or coordinated through the multi-jurisdictional CAC process. Members in the Noridian footprint should confirm L40265’s posting status directly with the contractor; its four siblings are verified, and Noridian participated in the same joint effort, but I have not independently confirmed the final document.


What came back

Sympathetic blocks for CRPS. This is the headline reversal. Stellate ganglion and lumbar sympathetic blocks moved from “investigational” to covered, conditionally. The conditions are demanding and every one of them is a documentation requirement:


  • IASP-criteria diagnosis: continuing pain disproportionate to the inciting event, at least one symptom in three of four categories (sensory, vasomotor, sudomotor/edema, motor/trophic), at least one sign on examination in two of four, and no better explanation
  • CRPS Severity Score documented at baseline, including pain intensity and functional impairment
  • Standard-of-care options tried without improvement, with the treating provider documenting that no alternatives remain
  • Ongoing care by an interdisciplinary or multidisciplinary team addressing psychological effects and functional impairment


For repeat blocks, add ≥50% immediate pain reduction and objective evidence of sympathetic blockade: transient Horner’s syndrome for stellate; for lumbar sympathetic, a ≥2°C rise in the ipsilateral foot or a ≥1.5°C interfoot differential at twenty minutes post-block. Beyond five lifetime blocks, you must document a sustained five-point CSS decrease from baseline lasting three months or longer.


Note how that ceiling was set. Absent any guideline or moderate-quality trial on optimal frequency, the contractors pulled national Medicare claims for 64510 and 64520 from December 2015 through 2025, found 80% of beneficiaries received one to five blocks, and adopted that as the threshold. This is worth flagging in future comments. Utilization is a description of practice, not a measure of medical necessity, and enshrining the observed distribution as a coverage limit converts current practice into a permanent ceiling.


Genicular procedures. Diagnostic genicular nerve injection is covered as the gateway to denervation when all of the following are met: moderate-to-severe OA with pain and disability documented on a validated scale, pain ≥3 months with documented failure of conservative care as tolerated, and radiographic KL grade 3–4. Exclusions: intra-articular injection or knee surgery within three months, inflammatory arthropathy, non-FDA-designated injectates, and high injectate volume — the LCD specifies 0.3–0.5 mL on the rationale that larger volumes destroy prognostic accuracy. Two diagnostic sessions per knee.


Ablation, by radiofrequency or cryoneurolysis, requires ≥50% improvement in pain or function sustained at least three months after the diagnostic injection (difficult to achieve), plus documentation that the patient is a poor surgical candidate or has declined arthroplasty. Two radiofrequency sessions per knee per rolling twelve months.


One documentation trap deserves emphasis: the pain scale must be the same scale at baseline and after each diagnostic procedure. A baseline NRS followed by a post-procedure VAS does not satisfy the criterion. Fix your templates now.


Lifetime caps removed. Median nerve injection converts from a lifetime allowance to a frequency limit: up to three per same median nerve at intervals of no less than two months, individualized to documented response. The Morton’s neuroma lifetime limit was likewise removed.


What did not come back

  1. Ganglion impar block and denervation: investigational, non-covered, on a very-low-certainty finding across risk of bias, imprecision, indirectness, and inconsistency.
  2. Therapeutic genicular injection: non-covered — the contractors accepted the nerve as an ablation target while rejecting the block as standalone therapy.
  3. Genicular ablation after total knee arthroplasty, outside the perioperative period: non-covered.
  4. The explanation-of-changes section records substantial new literature submitted for occipital, suprascapular, and pudendal nerve blocks but does not record a coverage change for any of them, and the thoracic section states explicitly that no coverage change was made. Members should read sections F through L of their own jurisdiction’s document directly before assuming any of these moved.
  5. The catch-all survives intact: any therapeutic peripheral nerve injection or denervation not listed as covered is non-covered.


The Bottomline - Pudendal nerve blocks and intercostal nerve blocks: Not Covered.


Two provisions that will generate denials in compliant practices


Anesthesia. Moderate sedation, deep sedation, general anesthesia, and monitored anesthesia care are declared usually unnecessary or rarely indicated for nerve injections, and therefore not reasonable and necessary. Needle phobia and anxiety are addressed by name — the LCD states that oral anxiolytics typically suffice. Exceptions require documentation establishing the need for the specific patient. A standing practice protocol will not survive review.


Image guidance. Ultrasound is covered only where necessary to identify the nerve and visualize needle placement. Fluoroscopy is covered for reasonable and necessary peripheral nerve RFA. Critically, image guidance performed for a non-covered injection is itself non-covered — a denied primary procedure takes the guidance code with it.


Before October 25

  1. Pull your jurisdiction’s Billing and Coding Article, not just the LCD. The CPT and ICD-10 detail lives there, and those articles drive the claim edits.
  2. Rebuild CRPS and genicular templates around the named criteria — CSS at baseline, temperature differential with time stamp, same pain scale throughout, explicit surgical-candidacy statement. These are not clinical niceties; they are the coverage criteria.
  3. Decide now which services become patient responsibility and build the ABN workflow before the first denial, not after it.
  4. Audit your sedation documentation. If MAC is routine in your practice for nerve injections, that changes October 25.


The unfinished work

The sections that moved, moved because evidence arrived. The sections that did not move — ganglion impar, therapeutic genicular injection, post-arthroplasty ablation, pudendal nerve blocks, intercostal nerve blocks, and the several nerves where new literature was logged but coverage was not changed — did not move because the submitted evidence was judged insufficient in certainty, not because it was ignored.


That is a solvable problem, and it is ours to solve. The reconsideration pathway stays open. What these documents establish is that the contractors will revise a coverage determination when the evidence supports it. What they also establish is the standard: GRADE-appraised, Medicare-applicable, adequately powered, and long enough to matter. Registries, pragmatic trials, and prospective outcome data in the over-65 population are no longer academic exercises. They are the mechanism.

 

Prepared from the final LCD texts posted to the CMS Medicare Coverage Database, notice period September 10 – October 24, 2026. Verify L40265 (Noridian) status and read sections F–L of your own jurisdiction’s document before relying on any summary, including this one.

 

SAVE THE DATE - APRIL 15-17, 2027

Save the date for the American Society of Interventional Pain Physicians' 29th Annual Meeting, April 15 - 17, 2027, in Orlando, Florida.


This flagship educational event will bring together physicians, researchers, and healthcare professionals from across the country for three days of cutting-edge education, collaboration, and professional networking.


Attendees can look forward to our most comprehensive Annual Meeting yet, featuring new educational topics, expanded faculty participation, and innovative program enhancements designed to keep you at the forefront of interventional pain management.


Mark your calendar now and plan to join us in Orlando as we continue advancing excellence in interventional pain management. Additional program details and faculty announcements will be released soon.


Register by October 1, 2026, to receive a 10% Early Bird Discount.

 

CMS Publishes Final Ambulatory Specialty Model (ASM) Participant List


CMS has published the final list of Ambulatory Specialty Model (ASM) participants.


Click here to find out if you are included in the final list.

 

ASIPP is expanding opportunities for Residents and Fellows at the 2027 Annual Meeting, with more ways to present, participate, connect, and represent fellowship programs.


Present Your Research  |  Connect with Program Directors

Represent Your Program  |  Programming for Residents & Fellows


Ready to Take Your Place?

Residents and Fellows can submit an abstract to share their research at ASIPP 2027 or apply for a scholarship to help make attending the Annual Meeting possible.

ASIPP is proud to launch our Resident and Fellow Mentorship Program. This initiative is designed to connect trainees with experienced pain physicians to foster professional growth, provide guidance, and strengthen the future of our specialty.


Each mentor would be paired with one to two trainees, but can take more if interested. Trainees will be responsible for initiating introductions and arranging at least one to two video calls per year. These sessions will provide opportunities for mentees to seek advice on clinical decision-making, career planning, research opportunities, and professional development.


We believe that your experience, expertise, and insight can have a lasting impact on the next generation of pain physicians. By volunteering as a mentor, you will play a critical role in shaping the future of our field and ensuring that ASIPP continues to cultivate excellence in interventional pain medicine.


If you are interested in serving as a mentor, please confirm your participation by filling out the appropriate form below.

Our Sponsor

ASIPP is pleased to announce the launch of the Regenerative and Longevity Medicine Section!


This section reflects the growing importance of regenerative and longevity medicine—fields dedicated to restoring health, enhancing vitality, and extending the healthy years of life. From stem cell therapies and tissue engineering to gene therapy and orthobiologics, these disciplines are transforming the way we approach pain management and age-related decline.


Section membership offers:

  • Access to ASIPP’s physician database and future data registry
  • Opportunities for certification and continuing education
  • Section-exclusive resources and updates


No additional cost for ASIPP members!

abipp logo

Apply now for one of the following 2026 dates:


October 24,

November 14,

& December 12




  • ABIPP Part I

Four (4) hour virtual exam


  • ABIPP Path – Combined CCPM/ CSM Exam

For those with subspecialty in Pain Medicine

Two (2) hour virtual exam


  • ABIPP Competency Exam in IPM

For those without primary board certification

Two (2) hour virtual exam


  • ABIPP Competency Exam in Regenerative Medicine

Two (2) hour virtual exam


  • Controlled Substance Management Competency Exam

Two (2) hour virtual exam


  • Documentation, Coding, Compliance, Practice Management Competency Exam

Two (2) hour virtual exam

Exam Dates

Study Finds Huge Regional Variability in 'Low-Value' Orthopedic Services for Vets

Patients in one place may get Medicare-paid procedures 10 times as often as elsewhere

 

Key Takeaways


• Some orthopedic procedures and diagnostics have been deemed "low value" because costs and risks often outweigh likely benefits.


• This study examined regional variations in how often five such services were provided to veterans and paid by Medicare.


It found substantial variability but with no clear regional patterns or correlations among the five low-value services.

So-called low-value orthopedic procedures, such as vertebroplasty for patients with asymptomatic spinal fractures, may be performed on veterans at dramatically different rates from one place to another, analysis of Medicare data showed.


In some hospital referral regions, certain low-value procedures were performed on one-quarter of Medicare-enrolled veterans at rates above 72 per 100 persons, while the same procedures were done elsewhere on hardly anyone, according to Samantha Auty, PhD, and colleagues at Boston University in Massachusetts.


Click here to read the full article.

 

Our Sponsor

Our Sponsor

Pain Medicine Case Reports (PMCR) and Editor-in-Chief Alaa Abd-Elsayed, MD, PhD would like to invite you to submit case reports and case series to the PMCR journal. Your article will be published free of charge.


Open access journals are freely available online for immediate worldwide open access to the full text of published articles. There is no subscription fee for open access journals. Open access journals are no different from traditional subscription-based journals: they undergo the same peer review and quality control as any other scholarly journal.


Interested in becoming a member of the PMCR Editorial Board?

Editorial board members are asked to review 2-6 manuscripts per year. Please submit your most up-to-date CV to sgold@asipp.org for consideration.


For more information or to submit your articles, click here.

We are excited to announce that Pain Medicine Case Reports (PMCR) journal (eISSN 2768-5152) has been accepted for inclusion in MEDLINE and PubMed, the prestigious bibliographic database of the U.S. National Library of Medicine. PMCR, a companion publication to the prestigious Pain Physician journal by ASIPP, joins its counterpart in achieving indexing in both MEDLINE and PubMed, marking ASIPP’s dual presence in these renowned databases.


The inclusion of PMCR journal in MEDLINE signifies a higher level of selectivity, as MEDLINE consists of the top 5,200 biomedical journals. This indexing also means that articles from PMCR will be searchable using NLM Medical Subject Headings (MeSH terms) and other metadata.


The selection for MEDLINE follows a rigorous evaluation process by reviewers from the Literature Selection Technical Review Committee (LSTRC). According to their criteria, the scientific quality of a journal’s content is the primary factor considered for indexing.


We extend our congratulations to the Pain Medicine Case Reports Editor-in-Chief, Deputy Editor-in-Chief, Journal Team, and Editorial Board for this achievement, which underscores the significance and excellence of this esteemed journal.

 

CASE REPORTS

Long-Term Tapentadol Use for Neuropathic Pain in a Hemodialysis Patient with End-stage Renal Disease: A Case Report


Mattison Shepherd, PharmD, and Morgan Bruketta, PharmD

Dorsal Root Ganglion Stimulation for Chronic Postoperative Abdominal Pain: A Case Report


Sidharth Sahni, DO, DPT, Harrison Jordan, DO, Anishinder Parkash, MD, Ruben Dovlatyan, DO, David Jevotovsky, MD, Blanka Heary, PA, and Michael E. Farrell, II, MD

Iatrogenic Femoral Neuropathy Mimicking Meralgia Paresthetica Following Groin Flap Surgery: A Case Report


Isra Hasnain, MD, and Kashif Manzar, MS

 
 
 

POSITION STATEMENT

Peripheral Nerve Stimulation Is Medically Necessary and Clinically Validated and Can No Longer Be Deemed Experimental



Peter S. Staats, MD, Timothy Deer, MD, Sean Li, MD, Konstantin Slavin, MD, Sayed Wahezi, MD, Miles Day, MD, Paul Christo, MD, Jason S. Eldrige, MD, Steven P. Cohen, MD, Jennifer Hah, MD, David Dickerson, MD, Hemant Kalia, MD, Robert Levy, MD, PhD, Alan D. Kaye, MD, PhD, Mahendra R. Sanapati, MD, and Laxmaiah Manchikanti, MD

SYSTEMATIC REVIEWS

Safety and Effectiveness of Different Approaches for Epidural Steroid Injections in Lumbar Spinal Stenosis: A Systematic Review and Meta-Analysis


Igor Wilderman, Francesca Sarzetto, Tina Didari, Rotem Frish Manor, and Seyed Kourosh Ghavami Riabi

Comparative Efficacy of Dexmedetomidine and Esketamine on Postoperative Sleep Disturbances and Analgesia: A Systematic Review and Network Meta-Analysis


Ting Jiang, Rui Zhao, Yingli Zhang, Rui Zhang, Xiuqing Wu, Lina Jin, Yukun Huang, Yiwei Zhang, Wojciech Czyzewski, Grzegorz Staskiewicz, Karol Pruszynski, Changshun Huang, and Binbin Zhu




ASIPP is in collaboration with Curi Medical Liability Program




Since this malpractice insurance program officially launched in November 2018, ASIPP has signed up hundreds of providers with an average savings of 30%. This is professional liability insurance tailored to our specialty and will stand up for us and defend our practices. 

 

Curi is a full-service advisory firm that serves physicians and their practices. Their valued advice is grounded in your priorities and elevated in your outcomes. They are driven by a deep understanding of your specific circumstances in medicine, business, and life. To read a few important points to keep in mind about the program, including discounts, administrative defense, cyber coverage, aggressive claims handling, and complimentary risk management CME activities, visit our website.



IMPORTANT UPDATE

SPRINT no longer classified as PNT 



SPR is happy to announce an important update regarding Humana Medicare Advantage. As of May 1, Humana is now recognizing SPRINT as a PNS therapy. Previously, SPRINT was categorized as PNT (Percutaneous Nerve Stimulation), which allowed denials on the grounds that the therapy fell outside the NCD.


Additional details are as follows:

Payer: Humana Medicare Advantage (click here to view policy)

Policy Title: Peripheral Nerve Stimulators

Policy changes: SPRINT no longer misclassified as PNT and is now appropriately classified as PNS. Humana is applying the Noridian Medicare LCD criteria to ALL PNS devices – Including SPRINT PNS!

Effective Date: 5/1/2025


Click here to view a PDF of the official policy update.

 

Group Purchasing Organization Offer Better Pricing and Creates Added Value


ASIPP has formed a partnership with Henry Schein and PedsPal, a national GPO that has a successful history of negotiating better prices on medical supplies and creating value-added services for independent physicians. Working with MedAssets, PedsPal provides excellent pricing on products like contrast media that alleviate some of the financial pressures you experience today.



Learn More


For updated information concerning tariffs on products, click here.

 
 

ASIPP, Fedora Healthcare Solutions Partnership


ASIPP offers our members the benefit of a unique revenue cycle management/ billing service.



We have received a tremendous amount of interest in the ASIPP billing and coding program.




Click here to learn more about the negotiated rate for practices and more!

Like and Follow ASIPP on Facebook, X, LinkedIn,

and YouTube for the most up-to-date news

related to you, your practice, and your patients!